

Shilpa Medicare Limited

Corporate & Admin Office:

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbsilpa.com, Web: www.vbsilpa.com
CIN: L85110KA1987PLC008739

Dated: 11 Mar, 2023

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549

US FDA Inspection of Shilpa Medicare Limited, Unit VII, Analytical Services Division

This is to inform you that the Company’s Analytical Services Division situated at Unit 7, Nacharam, Hyderabad, Telangana has been inspected by US FDA during 08 Mar 2023 to 10 Mar 2023. This is a full GMP inspection.

The inspection is closed with 2 minor observations, which are related to improvements in existing procedures and are addressable.

The Company will be submitting the responses to US FDA observations within stipulated timeline and will work towards implementing the corrective actions to address the observations.

This is the second US FDA inspection on the site. The initial inspection was done during Apr 2022, for which the GMP clearance (EIR) was issued in July 2022.

The facility is involved in analytical testing of drug products, drug substances, raw materials & packing materials. It is also engaged in analytical method validations, method transfers and conduct of other miscellaneous studies. This facility is involved in the testing of US/EU & other markets commercial batches.

With Regards,
For **SHILPA MEDICARE LIMITED**

Ritu Tiwary
Company Secretary & Compliance officer